LFCR Lifecore Biomedical, Inc.
Legal ·
Carew v. Lifecore Biomedical names the company and unnamed executive officers. The final approval hearing was held on July 28, 2026. A separate New York suit by 22NW Fund continues against the company.
The deal is valued at up to $663.7 million if performance milestones are met. Contingent value rights could lift total payout to $9.67 per share.
The contract manufacturer received $7 million at closing and expects the rest in three tranches over 18 months. It says current capacity supports up to $300 million in annual revenue.
Lifecore Biomedical, Inc., based in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (CDMO) for complex sterile injectable pharmaceutical and medical device products. It describes itself as a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA), made with a fermentation-based process it developed in 1981. Lifecore makes HA in bulk form and in filled syringes and vials for customers injectable products, including ophthalmic and orthopedic applications. Its development services include analytical method development, formulation development, sterile filtration, process scale-up, stability studies and production of materials for clinical studies. The company also develops highly viscous non-HA-based sterile injectable products with customers and operates three cGMP facilities. In September 2024 it installed a new fully automated aseptic isolator filler, which it said doubled its revenue-generating capacity to support up to approximately 00 million in annual revenue-generating capacity. Its customer relationships range from 20 years to nearly 40 years.
| Product or program | What it is | Stage |
|---|---|---|
| Hyaluronic acid (HA) | Pharmaceutical-grade, non-animal-sourced HA in bulk and in filled syringes and vials | |
| Aseptic filling services | Aseptic filling of complex, highly viscous injectables in syringes, vials and cartridges | |
| Non-HA viscous sterile injectables | Highly viscous non-HA-based sterile injectable products developed with customers |
| Line | FY ended May 25, 2025 | FY ended May 26, 2024 |
|---|---|---|
| Research and development | $8.3 million | $8.6 million |
| Net income (loss) | -$38.7 million | $12.0 million |
| Cash from operations | -$206,000 | $257,000 |
| Cash and equivalents | $8.3 million | $8.5 million |
Our latest story on this, dated Oct 20, 2026: "Lifecore reports July hearing on securities class action settlement". The story links the filing or release it is based on. Read the story.
Our latest story on this, dated Oct 20, 2026: "Lifecore reports July hearing on securities class action settlement". The story links the filing or release it is based on. Read the story.
Lifecore Biomedical, Inc. trades under the ticker LFCR on NASDAQ.
Lifecore Biomedical, Inc. is listed on NASDAQ. Our directory also records these other listings: GETTEX:LDE.
The SEC Central Index Key (CIK) for Lifecore Biomedical, Inc. is 1005286. Its filings are on SEC EDGAR.
37,853,060 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-05.
Our directory records Lifecore Biomedical, Inc. under United States.
Our directory classifies Lifecore Biomedical, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.
The ISIN recorded for Lifecore Biomedical, Inc. is US5147661046.
aibio.space lists Lifecore Biomedical, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
SEC records list its state or country of incorporation as DE.
Lifecore Biomedical, Inc., based in Chaska, Minnesota, is a fully integrated contract development and manufacturing organization (CDMO) for complex sterile injectable pharmaceutical and medical device products. It describes itself as a leading U.S. manufacturer of pharmaceutical-grade, non-animal-sourced hyaluronic acid (HA), made with a fermentation-based process it developed in 1981.
Hyaluronic acid (HA): Pharmaceutical-grade, non-animal-sourced HA in bulk and in filled syringes and vials
Aseptic filling services: Aseptic filling of complex, highly viscous injectables in syringes, vials and cartridges
Lifecore Biomedical, Inc. reported a net loss of $38.7 million for the fiscal year ended May 25, 2025, and used $206,000 of cash in operations, per its annual report to the SEC.
Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01,7.01,9.01). Source
Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). Source
Reported a financing. SEC Form 8-K (Items 7.01). Source
Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,7.01,9.01). Source
Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio